Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EYN-1601
- Development stage
- Unknown
- Lead developer
- Hyperion DeFi
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
EYN-1601 is a pharmaceutical ophthalmic formulation of phenylephrine 10% delivered via a microdosing device (Optejet, developed by Eyenovia) for the induction of mydriasis (pupil dilation) in the context of ophthalmic procedures. The drug uses a high-precision piezo-ejection microdroplet system, which enables delivery of a small volume (~7–8 µL) of the mydriatic agent, phenylephrine, directly to the eye. The clinical studies have demonstrated comparable efficacy and safety to standard phenylephrine eyedrops, with the advantages of potentially reduced systemic absorption and improved tolerability due to lower delivered dose and preservative content. Developed and tested primarily for procedural mydriasis[1][5][7][8].
- Brand names
- EYN-1601EYN1601EYN 1601
- Other names
- EYN-1601EYN1601EYN 1601
02
Targets
ADRA1A (α1A)
Beyond the preview
Go deeper on EYN-1601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EYN-1601.